Analysis Calliditas: Great value can be released
10 Oct 2019
Calliditas has a leading postion in the development of a treatment for the chronic kidney disease IgA-nephropathy. The prospects for success in the ongoing Phase III trial are promising, in our view. Strong finances provides the means to reach very important value inflection points.
Read the full report (Swedish) here.